National
‘Don’t Go Home!’ until ‘Don’t Ask’ is done
Demonstrators demand Senators extend session
(Blade photo by Michael Key)
Supporters of open service in the U.S. military rallied on Capitol Hill Friday to urge the Senate to stay in session for as long as needed until lawmakers repeal “Don’t Ask, Don’t Tell.”
Braving the December cold, around 100 participants gathered near the U.S. Capitol at the Upper Senate Park for the event, which was organized by the Servicemembers Legal Defense Network.
Those in attendance shouted the refrain “Don’t Go Home!” as they demanded that lawmakers continue work on Capitol Hill until “Don’t Ask, Don’t Tell” is repealed.
The rally comes in the wake of a devastating defeat that supporters of “Don’t Ask, Don’t Tell” repeal suffered on Thursday when the Senate failed to move ahead with major defense legislation containing repeal language by a vote of 57-40, three votes short of the 60-vote threshold necessary to end a filibuster.
Aubrey Sarvis, executive director of the Servicemembers Legal Defense Network, told the crowd the vote represented a setback, but said supporters of repeal have “reported back for duty.”
“In this lame duck, we speak everyday for all LGBT service members as they fight for our freedom,” Sarvis said. “In this Congress, we raise our voices as one and say, ‘Senators, kill this law, kill this law before you go home!'”
A number of veterans and current service members — gay and straight — addressed the rally and called for an end to the military’s gay ban.
Mike Almy, a gay former Air Force communications officer who was discharged in 2008 under “Don’t Ask, Don’t Tell,” also called on the Senate to stay in session until work is done on lifting the military’s gay ban.
“The Senate wants … to go home to their families and not do their duties and sit by warm fireplaces comfortably in their homes for Christmas while the work remains unfinished,” Almy said. “If I can serve overseas in harm’s way for four Christmases defending our nation, the Senate can certainly do the same.”
Senate Majority Leader Harry Reid (D-Nev.) has set Dec. 17 as the target date for adjournment for the Senate, although some lawmakers, including Sens. Joseph Lieberman (I-Conn.) and Mark Udall (D-Colo.), have said they’re willing to stay in session through the week before Christmas to repeal “Don’t Ask, Don’t Tell.”
Ret. Maj. Gen. Dennis Laich, who’s straight served in the Army for 35 years, said repeal of “Don’t Ask, Don’t Tell” is needed because the ban compromises the integrity of the U.S. military.
“‘Don’t Ask, Don’t Tell’ acknowledges that gays and lesbians serve in our military, but pretends they’re not there,” he said. “It destroys the values of that institution and on which it is based.”
Should the Senate not repeal “Don’t Ask, Don’t Tell,” Laich predicted what he called a “Spartacus moment” in which the estimated 66,000 gay and lesbian people serving in the military would declare their sexual orientations under the current law.
“How much does it cost to process the discharge of 66,000 service members?” Laich said. “How much does it cost to recruit and train their replacements? How long will it take to recruit and train those replacements? And how vulnerable will America be during this self-imposed national security crisis?”
Speakers at the rally had particularly strong words for senators who were among the “no” votes on Thursday preventing the “Don’t Ask, Don’t Tell” legislation from coming to the Senate floor.
Almy, an Ohio native whose family still lives in the state, said he was particularly disappointed in Sen. George Voinovich’s (R-Ohio) decision to vote against the legislation. The senator was considered a swing vote on moving forward with “Don’t Ask, Don’t Tell.”
“Yesterday, you shamed me with your vote as well as the rest of the Ohio veterans,” Almy said. “This is going to be your legacy. You are on the wrong side of history here Sen. Voinovich. I call on you here specifically to stay here in Washington and not leave.”
Two speakers who hailed from West Virginia also had harsh words for Sen. Joe Manchin (D-W.Va.), the only Democrat who voted against the motion to proceed Thursday on “Don’t Ask, Don’t Tell” repeal legislation.
Sgt. Jared Towner, a straight member of the West Virginia Army National Guard, said the “very, very established progressive youth element” in his state is disappointed in Manchin for his vote and could decline to back him when he’s next up for election in two years.
“We are the people that are going to be there — or we are the people that are not going to be there — in 2012,” Towner said. “You have to be there for us.”
Former Army Sgt. Pepe Johnson, a field artilleryman and Clarksburg, W.Va., native who was discharged under “Don’t Ask, Don’t Tell” in 2003, said he was “embarassed” because Manchin “decided to be a lone ranger” and vote against repeal.
“He said he’d only been in office for three weeks, so he didn’t have a chance to hear from the people of West Virginia,” Johnson said. “Well, Joe Manchin, if you can’t hear now, you better get a hearing aide!”
Many participants echoed the general tenor of the rally that Congress should stay in session for the time that’s needed to repeal “Don’t Ask, Don’t Tell” before going home.
Toby Quaranta, 25 and a gay D.C. resident, said he participated in the rally because he wants “people everywhere to know” that supporters of “Don’t Ask, Don’t Tell” repeal don’t want lawmakers to adjourn until the law is off the books.
“I think the Senate has a responsibility to the service members and to the people who just re-elected a lot of them to make sure that they get their business done before they leave town,” Quaranta said.
Bridget Geraghty, 25 and a lesbian D.C. resident, expressed frustration that the Senate was unable to act on “Don’t Ask, Don’t Tell” repeal when the vote came before the chamber on Thursday.
“I was seriously disappointed, but I guess not really surprised,” she said. “It’s never a surprise when Republicans don’t do what they’re supposed to do, and I think it was ridiculous that they are not letting this happen.”
One group of rally participants held up a banner during reading “In memory of Seaman August Provost, 1979-2009: All LGBT employees of the Department of Defense deserve EQUAL RIGHTS!”
Provost, a gay Navy seaman stationed at Camp Pendleton, Calif., was found dead on base last year and was possibly murdered because of his sexual orientation. He reportedly had complained to family members that was being harassed before he was killed.
Also among the rally participants was Rea Carey, executive director of the National Gay & Lesbian Task Force. Following the rally, she told the Blade she was “extremely disappointed” in the Senate vote on Thursday, but expected repeal advocates to continue toward their goal.
“I’m pleased that there are senators who are going to continue to push in this lame duck, and all of us at this rally and elsewhere around the country are going to push with them,” she said.
Many repeal advocates are pinning their hopes on new stand-alone legislation that Lieberman introduced in the Senate following the defeat on Thursday of the fiscal year 2011 defense authorization bill. The new stand-alone measure is identical to the repeal provision in the defense legislation.
Following the rally, Sarvis expressed optimism about the chances of passing the stand-alone repeal legislation in the lame duck and said repeal advocates are working to come up with 60 votes to move forward with the legislation in the Senate.
“The defense authorization bill, as a vehicle, became stale for a number of reasons,” he said. “Some senators talked about process or the procedure. I think our chances may well improve on a clean bill — clean in the sense of new introduction.”
Sarvis said attaching repeal language to the continuing resolution that Congress will soon vote on to extend funding for the U.S. government is another option on the table.
Still, Sarvis said using this measure as a vehicle for repeal would be “one of the last opportunities” for legislatively ending the military’s gay ban this year.
“Normally, the CR sometimes moves sometimes literally in the final hours,” Sarvis said. “So that is clearly an option that is out there. That’s why SLDN has put it on the table.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Using movement to boost your mental health during holidays
Reasons to be optimistic about 2026
America is going in the wrong direction for intersex children
Rush reopens after renewing suspended liquor license
Long-awaited ‘Pillion’ surpasses the sexy buzz
